Targeting IL-23: Insights into the pathogenesis and the treatment of psoriasis

Indian Journal of Dermatology

Volumn 55, Issue 2, 2010, Pages 171-175

  Lima, Hermenio Cavalcante ^a   Kimball, Alexandra Boer ^b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anti IL 12 23; Biological treatment; IL 12; IL 17; IL 23; Psoriasis

Indexed keywords

BRIAKINUMAB; CYTOKINE; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR ANTAGONIST; CYTOTOXIC AGENT; GAMMA INTERFERON ANTIBODY; INTERFERON ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23; INTERLEUKIN 23 ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOLOGICAL THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOPHENOTYPING; KERATINOCYTE; OPPORTUNISTIC INFECTION; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN TARGETING; PSORIASIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 77952019850     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.62760     Document Type: Conference Paper

References (50)

1. Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders. Int Rev Immunol 1998;17:217-28. (Pubitemid 29014551)
2. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
3. Squire B. The etiology of psoriasis. Br Med J 1873;1:141.
4. Heaney JH. The etiology and treatment of psoriasis. Br Med J 1927;2:1136-7.
5. Ingram JT. The approach to psoriasis. Br Med J 1953;2:591-4.
6. Harber LC, March C, Ovary Z. Lack of passive cutaneous anaphylaxis in psoriasis. Arch Dermatol 1962;85:716-9.
7. Aswaq M, Farber EM, Moreci AP, Raffel S. Immunologic reactions in psoriasis. Arch Dermatol 1960;82:663-6.
8. Landau J, Gross BG, Newcomer VD, Wright ET. Immunologic response of patients with psoriasis. Arch Dermatol 1965;91:607-10.
9. Harris CC. Malignancy during methotrexate and steroid therapy for psoriasis. Arch Dermatol 1971;103:501-4.
10. Shuster S. Research into psoriasis-the last decade. Br Med J 1971;3:236-9.
11. Hunter JA, Ryan TJ, Savin JA. Diseases of the skin. Present and future trends in approaches to skin disease. Br Med J 1974;1:283-4.
12. Braun-Falco O, Christophers E. Structural aspects of initial psoriatic lesions. Arch Dermatol Forsch 1974;251:95-110.
13. Krueger GG, Jederberg WW, Ogden BE, Reese DL. Inflammatory and immune cell function in psoriasis: II. Monocyte function, lymphokine production. J Invest Dermatol 1978;71:195-201. (Pubitemid 9082182)
14. Krueger GG, Jederberg WW. Alteration of HeLa cell growth equilibrium by supernatants of peripheral blood mononuclear cells from normal and psoriatic subjects. J Invest Dermatol 1980;74:148-53.
15. Champion RH. Psoriasis and its treatment. Br Med J (Clin Res Ed) 1981;282:343-6. (Pubitemid 11173639)
16. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983;275:181-9.
17. Baker BS, Swain AF, Griffiths CE, Leonard JN, Fry L, Valdimarsson H. The effects of topical treatment with steroids or dithranol on epidermal T lymphocytes and dendritic cells in psoriasis. Scand J Immunol 1985;22:471-7. (Pubitemid 16174322)
18. Bos JD, Krieg SR. Psoriasis infiltrating cell immunophenotype: Changes induced by PUVA or corticosteroid treatment in T-cell subsets, Langerhans' cells and interdigitating cells. Acta Derm Venereol 1985;65:390-7.
19. Lieden G, Skogh M. Plasma exchange and leukapheresis in psoriasis-no effect? Arch Dermatol Res 1986;278:437-40. (Pubitemid 16022292)
20. Valdimarsson H, Bake BS, Jónsdótdr I, Fry L. Psoriasis: A disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986;7:256-9. (Pubitemid 17022412)
21. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T-cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102:145-9. (Pubitemid 24060399)
22. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T-cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57. (Pubitemid 16136806)
23. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T-cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T-cells in psoriatic patients. J Invest Dermatol 1999;113:752-9.
24. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-912. (Pubitemid 40627816)
25. Nickoloff BJ, Schroder JM, von den Driesch P, Raychaudhuri SP, Farber EM, Boehncke WH, et al. Is psoriasis a T-cell disease? Exp Dermatol 2000;9:359-75.
26. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T-cells. Nature 1995;378:88-91.
27. Biedermann T, Rocken M, Carballido JM. TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin. J Investig Dermatol Symp Proc 2004;9:5-14. (Pubitemid 38096191)
28. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+T-cells. J Immunol 1995;154:5071-9.
29. Trinchieri G. Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv Immunol 1998;70:83-243. (Pubitemid 128678837)
30. Hong K, Berg EL, Ehrhardt RO. Persistence of pathogenic CD4+ Th1-like cells in vivo in the absence of IL-12 but in the presence of autoantigen. J Immunol 2001;166:4765-72. (Pubitemid 32233766)
31. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999;162:7480-91. (Pubitemid 29277728)
32. Monteleone I, Pallone F, Monteleone G. Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm 2009;2009:297645.
33. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30. (Pubitemid 38076484)
34. Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006;177:4917-26. (Pubitemid 44469828)
35. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T-cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-4. (Pubitemid 36801431)
36. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000;165:6107-15.
37. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T-cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32. (Pubitemid 41541790)
38. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
39. Lima XT, Abuabara K, Kimball AB, Lima HC. Briakinumab. Expert Opin Biol Ther 2009;9:1107-13.
40. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74. (Pubitemid 351671883)
41. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-708. (Pubitemid 34556153)
42. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: New players in the regulation of T-cell responses. Immunity 2003;19:641-4. (Pubitemid 37490789)
43. Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002;110:493-7. (Pubitemid 34919703)
44. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, et al. TNF is a potent anti-inflammatory cytokine in autoimmunemediated demyelination. Nat Med 1998;4:78-83. (Pubitemid 28133083)
45. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847-61.
46. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003;21: S24-34.
47. MacLennan C, Fieschi C, Lammas DA, Picard C, Dorman SE, Sanal O, et al. Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J Infect Dis 2004;190:1755-7. (Pubitemid 39487818)
48. Rudner XL, Happel KI, Young EA, Shellito JE. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect Immun 2007;75:3055-61.
49. Shear NH, Prinz J, Papp K, Langley RG, Gulliver WP. Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease. J Cutan Med Surg 2008;12: S1-10.
50. Chackerian AA, Chen SJ, Brodie SJ, Mattson JD, McClanahan TK, Kastelein RA, et al. Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect Immun 2006;74:6092-9.